Incannex Healthcare (IXHL) vs Shuttle Pharmaceuticals (SHPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Incannex Healthcare (IXHL) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 75.4% versus a loss of 87.4%. Incannex Healthcare is the larger company by market cap ($38.9 million vs $25.4 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | SHPH |
|---|---|---|
| Share price | $3.10 | $5.33 |
| Market cap | $38.89M | $25.40M |
| 1-day change | -3.13% | -4.05% |
| YTD return | -71.14% | -69.17% |
| 1-year return | -75.40% | -87.36% |
| EPS (TTM) | $-1.66 | $-16.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.91 | $55.90 |
| 52-week low | $2.49 | $2.58 |
| Distance from 52-week high | -79.21% | -90.47% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +502.58% | — |
| Average volume | 94.75K | 1.36M |
| Shares outstanding | 12.54M | 4.76M |
| Employees | 12 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IXHL has outperformed SHPH by 12.0 percentage points over the past year.
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
IXHL vs SHPH FAQ
Which is bigger, Incannex Healthcare or Shuttle Pharmaceuticals?
Incannex Healthcare (IXHL) is larger, with a market capitalization of $38.89M compared with $25.40M for Shuttle Pharmaceuticals (SHPH).
Which stock has performed better over the past year, IXHL or SHPH?
IXHL returned -75.40% over the past 12 months, compared with -87.36% for SHPH (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and Shuttle Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.